The new AUC for PET Myocardial Perfusion Imaging addresses several clinical scenarios for nuclear medicine. To improve utilization and guide providers to use nuclear medicine for coronary artery disease and cardiovascular risk stratification in a more appropriate way, the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the American College of Cardiology (ACC), the American Society of Nuclear Cardiology (ASNC), the Canadian Cardiovascular Society (CCS), the Canadian Society of Cardiovascular Nuclear and CT Imaging (CSCNCTI), the Society of Cardiovascular CT (SCCT), the American Heart Association (AHA), the American College of Physicians (ACP), and the European Association of Nuclear Medicine (EANM) have collaboratively developed criteria for the appropriate use imaging technologies to aid referring medical practitioners in the appropriate use of MPI and concurrent myocardial blood flow (MBF) assessment with PET (PET MPI).
SNMMI assembled an autonomous PET MPI Workgroup consisting of experts in the field of nuclear medicine with substantive knowledge in the use of PET MPI to review the scientific literature and develop consensus recommendations for the clinical use of this technology. The Oregon Health Science University's (OHSU) Evidence-based Practice Center (EPC) conducted a systematic review of existing evidence based on the scope and parameters the PET MPI Workgroup put together, which they used to make their recommendations for clinical use. This AUC addresses the CMS priority clinical area of coronary artery disease (suspected or diagnosed).
To view the development process, please click the following link: SNMMI AUC Development Process.